Everolimus-related unilateral abdominal lymphedema in a renal cancer patient: A case report

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F20%3A00078469" target="_blank" >RIV/00209805:_____/20:00078469 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/20:00117214

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571978/" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571978/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MD.0000000000022634" target="_blank" >10.1097/MD.0000000000022634</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Everolimus-related unilateral abdominal lymphedema in a renal cancer patient: A case report

Popis výsledku v původním jazyce

Rationale: Unilateral manifestation of lymphedema during everolimus therapy has been described only rarely, mostly in transplant recipients. Patient concerns: We report the first case of a patient who developed unilateral abdominal lymphedema, during a short period of everolimus treatment for renal cancer. Diagnosis: The abdominal asymmetry occurred only on the right side of the abdomen, neither ultrasound nor CT scan detected ascites but showed enlargement of the abdominal wall. The Naranjo Adverse Drug Reaction Probability scale was evaluated, in this case, a score of 6 indicated a probable adverse reaction to everolimus. Interventions: Discontinuation of everolimus therapy led to immediate alleviation and reduction of the lymphedema, with worsening once again after initiating retreatment with everolimus at a reduced dose. Outcomes: The patient&apos;s lymphedema recovered after discontinuation of everolimus. Lessons: This rare case demonstrates the importance of the selection of mammalian target of rapamycin inhibitors using caution, especially for patients with a high risk of developing lymphedema.

Název v anglickém jazyce

Everolimus-related unilateral abdominal lymphedema in a renal cancer patient: A case report

Popis výsledku anglicky

Rationale: Unilateral manifestation of lymphedema during everolimus therapy has been described only rarely, mostly in transplant recipients. Patient concerns: We report the first case of a patient who developed unilateral abdominal lymphedema, during a short period of everolimus treatment for renal cancer. Diagnosis: The abdominal asymmetry occurred only on the right side of the abdomen, neither ultrasound nor CT scan detected ascites but showed enlargement of the abdominal wall. The Naranjo Adverse Drug Reaction Probability scale was evaluated, in this case, a score of 6 indicated a probable adverse reaction to everolimus. Interventions: Discontinuation of everolimus therapy led to immediate alleviation and reduction of the lymphedema, with worsening once again after initiating retreatment with everolimus at a reduced dose. Outcomes: The patient&apos;s lymphedema recovered after discontinuation of everolimus. Lessons: This rare case demonstrates the importance of the selection of mammalian target of rapamycin inhibitors using caution, especially for patients with a high risk of developing lymphedema.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/LM2018128" target="_blank" >LM2018128: Český národní uzel Evropské sítě infrastruktur klinického výzkumu</a><br>

Návaznosti

—

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Medicine (Baltimore)

ISSN

0025-7974

e-ISSN

—

Svazek periodika

99

Číslo periodika v rámci svazku

42

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

"e22634"

Kód UT WoS článku

000589394700033

EID výsledku v databázi Scopus

2-s2.0-85094221345